Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473169 | 1.00 | NAAA (0.61) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL1416720 | 1.00 | NAAA (0.61) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL473280 | 1.00 | NAAA (0.61) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL1416698 | 1.00 | NAAA (0.61) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL35190 | 1.00 | NAAA (0.61) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL1837930 | 1.00 | NAAA (0.61) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL473104 | 1.00 | NAAA (0.61) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL104550 | 1.00 | NAAA (0.61) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL473289 | 1.00 | NAAA (0.61) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL76043 | 1.00 | NAAA (0.61) | NAAAEPHX1TSHRHTR2CHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0107850-B1 | AMINOGLYCOSIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-06 | — | — | EP | claimed |
| US-4493831-A | ANTIBIOTICS, VIRICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-15 | — | — | US | claimed |
| EP-0107850-A1 | Aminoglycoside derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-09 | — | — | EP | claimed |
| EP-3527600-B1 | ISOCYANATE COMPOSITION AND PRODUCTION METHOD FOR ISOCYANATE POLYMER | ASAHI CHEMICAL IND (JP) | 2025-07-09 | — | — | EP | disclosed |
| EP-3795561-B1 | METHOD FOR PRODUCING CARBAMATE AND METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2024-11-06 | — | — | EP | disclosed |
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| CN-112020493-B | Method for producing urethane and method for producing isocyanate | 旭化成株式会社 | 2023-04-21 | — | — | CN | disclosed |
| US-20230114799-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11548975-B2 | Isocyanate composition and method for producing isocyanate polymer | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2322504-A1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | Asahi Kasei Chemicals Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
| CN-101687991-A | Thermally stable alignment materials | ROLIC AG | 2010-03-31 | — | — | CN | disclosed |
| CN-101316615-A | Bifunctional metal chelating conjugates | MALLINCKRODT INC (US) | 2008-12-03 | — | — | CN | disclosed |
| US-5952316-A | FOR TREATING AUTOIMMUNE DISEASES, E.G., RHEUMATIOD ARTHRITIS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5719176-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548975-B2 | Isocyanate composition and method for producing isocyanate polymer | IDH3A, IDH2, IDH3B | NAAA 521/4885EPHX1 3187/4885TSHR 4885/4885 |
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | CPS1, ALKBH3, RCC1 | NAAA 57/4885EPHX1 1711/4885TSHR 4686/4885 |
| US-20230114799-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | IDH3A, IDH2, IDH3B | NAAA 456/4885EPHX1 3204/4885TSHR 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.